China’s Fast-Track Innovative Device Pathway Delivers For Few
Executive Summary
Less than 5% of applications for China’s fast-track device pathway have been approved, with the main reason for failure becoming clear.
You may also be interested in...
China's Medtech Regulatory Reforms Yet To Enter Steady Path
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.